RxDoctor Payments Data

Rajab Abukhadrah, MD

Gastroenterology · Clermont, FLNPI 1023083896

Payments from drug & device makers

$7,373in general payments, 2019–2025

Across 417 payments — averaging $17.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Pfizer$1K
  • Phathom Pharmaceuticals, Inc.$416
  • Boston Scientific$354
  • Johnson & Johnson$289
  • Sanofi$230
  • plus $1K from 22 others

What the payments were for

  • Consulting fees$170%
  • Travel & lodging$1462%
  • Food & beverage$7,04396%
  • Education$1142%
  • Gifts$531%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,373 in reported general payments places this provider in the 65th percentile of 1,388 gastroenterology providers in Florida.

See all gastroenterology providers in Florida

Medicare billing

Part B allowed, 2024
$239,733
Medicare patients
844
Services billed
2,024

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase77$268,609
ZenpepLipase/Protease/Amylase28$119,346
LinzessLinaclotide143$96,200
Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate14$38,889
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates338$21,679
Mesalamine25$17,386
VoqueznaVonoprazan Fumarate21$15,074
TrulancePlecanatide16$12,987
Dexlansoprazole DrDexlansoprazole26$11,759
Sucralfate127$10,439
Famotidine454$5,669
Omeprazole464$5,167
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg152$3,586
Lubiprostone17$3,562
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine54$2,708

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$3,582$364,810220 claims
Aimmune Therapeutics, Inc.Zenpep$111$119,34628 claims
Phathom Pharmaceuticals, Inc.Voquezna$416$15,07421 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$190$12,98716 claims
Ferring Pharmaceuticals Inc.Clenpiq$31$2,66716 claims
Braintree Laboratories, Inc.Sutab$76$2,49315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,388 gastroenterology providers in Florida.

Other gastroenterology in Clermont

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →